PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
企業コードPMCB
会社名PharmaCyte Biotech Inc
上場日Sep 11, 2003
最高経営責任者「CEO」Mr. Joshua N. (Josh) Silverman
従業員数2
証券種類Ordinary Share
決算期末Sep 11
本社所在地3960 Howard Hughes Parkway, Suite 500
都市LAS VEGAS
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号89169
電話番号19175952850
ウェブサイトhttps://pharmacyte.com/
企業コードPMCB
上場日Sep 11, 2003
最高経営責任者「CEO」Mr. Joshua N. (Josh) Silverman
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし